Research advances in hepatitis B virus-associated glomerulonephritis

Zhaoxia LI; Nan LI; Guijie XIN

doi:10.3969/j.issn.1001-5256.2023.03.027

Volume 39 Issue 3

Mar. 2023

Turn off MathJax

Article Contents

Abstract

References

Article Navigation > Journal of Clinical Hepatology > 2023 > 39(3): 651-656

PDF( 2004 KB)

Research advances in hepatitis B virus-associated glomerulonephritis

DOI: 10.3969/j.issn.1001-5256.2023.03.027

Department of Hepatology, The First Hospital of Jilin University, Changchun 130021, China

Research funding:

Jilin Province Health Department Key Laboratory Program (2018J043)

More Information

Corresponding author: XIN Guijie, xingj@jlu.edu.cn (ORCID: 0000-0002-0868-0317)
Received Date: 2022-06-23
Accepted Date: 2022-08-08
Published Date: 2023-03-20

Abstract

Abstract

There is are large number of patients with chronic hepatitis B virus (HBV) infection. HBV not only damages the liver, but also involves the kidney. Hepatitis B virus-associated glomerulonephritis (HBV-GN) is secondary glomerulonephritis caused by HBV infection, and it is one of the most common extrahepatic complications of HBV infection. HBV-GN is mainly observed in children and young and middle-aged adults, with varying degrees of proteinuria as the main clinical manifestation, and it may be accompanied by hematuria and hypertension. Membranous nephropathy is the most common pathological type, followed by membrano-proliferative glomerulonephritis and IgA nephropathy. HBV-GN has an insidious onset and lacks characteristic symptoms and pathological manifestations, and thus it may be easily confused with various types of glomerulonephritis, which may lead to missed diagnosis and misdiagnosis. HBV-GN has a complex pathogenesis involving various links such as immune disorders, direct viral damage, and genetics, among which the theory of immune complex deposition has been widely recognized. In recent years, some important advances have been made in the research on the pathogenesis, diagnosis, and treatment of HBV-GN. This article summarizes the above issues, so as to provide a reference for clinical diagnosis and treatment.
- Glomerulonephritis,
- Hepatitis B Virus,
- Diagnosis,
- Therapeutics

FullText(HTML)

References(41)

References

[1]	SCHWEITZER A, HORN J, MIKOLAJCZYK RT, et al. Estimations of worldwide prevalence of chronic hepatitis B virus infection: a systematic review of data published between 1965 and 2013[J]. Lancet, 2015, 386(10003): 1546-1555. DOI: 10.1016/S0140-6736(15)61412-X.
[2]	Polaris Observatory Collaborators. Global prevalence, treatment, and prevention of hepatitis B virus infection in 2016: a modelling study[J]. Lancet Gastroenterol Hepatol, 2018, 3(6): 383-403. DOI: 10.1016/S2468-1253(18)30056-6.
[3]	HUANG Y, SHI KW, ZHU XJ, et al. Disease spectrum of 9310 cases of renal biopsy pathological diagnosis from a single center in China[J]. J Cent South Univ(Med Sci), 2022, 47(5): 546-554. DOI: 10.11817/j.issn.1672-7347.2022.210487. 黄瑶, 施克雯, 朱雪婧, 等. 中国单中心9310例肾活检病理诊断疾病谱[J]. 中南大学学报(医学版), 2022, 47(5): 546-554. DOI: 10.11817/j.issn.1672-7347.2022.210487.
[4]	COMBES B, SHOREY J, BARRERA A, et al. Glomerulonephritis with deposition of Australia antigen-antibody complexes in glomerular basement membrane[J]. Lancet, 1971, 2(7718): 234-237. DOI: 10.1016/s0140-6736(71)92572-4.
[5]	FERDEK PE, JAKUBOWSKA MA, GERASIMENKO JV, et al. Bile acids induce necrosis in pancreatic stellate cells dependent on calcium entry and sodium-driven bile uptake[J]. J Physiol, 2016, 594(21): 6147-6164. DOI: 10.1113/JP272774.
[6]	DÖRING B, LVTTEKE T, GEYER J, et al. The SLC10 carrier family: transport functions and molecular structure[J]. Curr Top Membr, 2012, 70: 105-168. DOI: 10.1016/B978-0-12-394316-3.00004-1.
[7]	YAN H, ZHONG G, XU G, et al. Sodium taurocholate cotransporting polypeptide is a functional receptor for human hepatitis B and D virus[J]. Elife, 2012, 1: e00049. DOI: 10.7554/eLife.00049.
[8]	WANG R, WU Y, ZHENG B, et al. Clinicopathological characteristics and prognosis of hepatitis B associated membranous nephropathy and idiopathic membranous nephropathy complicated with hepatitis B virus infection[J]. Sci Rep, 2021, 11(1): 18407. DOI: 10.1038/s41598-021-98010-y.
[9]	LI D, GAO G, JIANG H, et al. Hepatitis B virus-associated glomerulonephritis in HBsAg serological-negative patients[J]. Eur J Gastroenterol Hepatol, 2015, 27(1): 65-69. DOI: 10.1097/MEG.0000000000000236.
[10]	PRESCOTT NA, BRAM Y, SCHWARTZ RE, et al. Targeting hepatitis B virus covalently closed circular DNA and hepatitis B virus X protein: recent advances and new approaches[J]. ACS Infect Dis, 2019, 5(10): 1657-1667. DOI: 10.1021/acsinfecdis.9b00249.
[11]	LIANG DY, SHA S, YI Q, et al. Hepatitis B X protein upregulates decoy receptor 3 expression via the PI3K/NF-κB pathway[J]. Cell Signal, 2019, 62: 109346. DOI: 10.1016/j.cellsig.2019.109346.
[12]	HAN W, LUO M, HE M, et al. HBx gene transfection affects the cycle of primary renal tubular epithelial cells through regulating cyclin expression[J]. Mol Med Rep, 2018, 18(2): 1947-1954. DOI: 10.3892/mmr.2018.9197.
[13]	LI M, HU L, ZHU F, et al. Hepatitis B virus X protein promotes renal epithelial-mesenchymal transition in human renal proximal tubule epithelial cells through the activation of NF-κB[J]. Int J Mol Med, 2016, 38(2): 513-520. DOI: 10.3892/ijmm.2016.2637.
[14]	FENG Y, CUI Y, GAO JL, et al. Resveratrol attenuates neuronal autophagy and inflammatory injury by inhibiting the TLR4/NF-κB signaling pathway in experimental traumatic brain injury[J]. Int J Mol Med, 2016, 37(4): 921-930. DOI: 10.3892/ijmm.2016.2495.
[15]	YANG YT, WANG X, ZHANG YY, et al. The histone demethylase LSD1 promotes renal inflammation by mediating TLR4 signaling in hepatitis B virus-associated glomerulonephritis[J]. Cell Death Dis, 2019, 10(4): 278. DOI: 10.1038/s41419-019-1514-4.
[16]	ZHOU Y, ZHU N, WANG X, et al. The role of the toll-like receptor TLR4 in hepatitis B virus-associated glomerulonephritis[J]. Arch Virol, 2013, 158(2): 425-433. DOI: 10.1007/s00705-012-1508-3.
[17]	LEE WM. Hepatitis B virus infection[J]. N Engl J Med, 1997, 337(24): 1733-1745. DOI: 10.1056/NEJM199712113372406.
[18]	STARKE A, LINDENMEYER MT, SEGERER S, et al. Renal tubular PD-L1 (CD274) suppresses alloreactive human T-cell responses[J]. Kidney Int, 2010, 78(1): 38-47. DOI: 10.1038/ki.2010.97.
[19]	LEE VW, QIN X, WANG Y, et al. The CD40-CD154 co-stimulation pathway mediates innate immune injury in adriamycin nephrosis[J]. Nephrol Dial Transplant, 2010, 25(3): 717-730. DOI: 10.1093/ndt/gfp569.
[20]	WANG X, WANG L, ZHU N, et al. Hepatitis B virus X protein modulates renal tubular epithelial cell-induced T-cell and macrophage responses[J]. Immunol Cell Biol, 2016, 94(3): 266-273. DOI: 10.1038/icb.2015.85.
[21]	WANG X, ZHOU Y, ZHU N, et al. The deposition of Notch1 in hepatitis B virus-associated nephropathy and its role in hepatitis B virus X protein-induced epithelial-mesenchymal transdifferentiation and immunity disorder in renal tubular epithelial cells[J]. J Viral Hepat, 2014, 21(10): 734-743. DOI: 10.1111/jvh.12244.
[22]	ZHEN J, ZHANG L, PAN J, et al. AIM2 mediates inflammation-associated renal damage in hepatitis B virus-associated glomerulonephritis by regulating caspase-1, IL-1β, and IL-18[J]. Mediators Inflamm, 2014, 2014: 190860. DOI: 10.1155/2014/190860.
[23]	BHIMMA R, HAMMOND MG, COOVADIA HM, et al. HLA class Ⅰ and Ⅱ in black children with hepatitis B virus-associated membranous nephropathy[J]. Kidney Int, 2002, 61(4): 1510-1515. DOI: 10.1046/j.1523-1755.2002.00287.x.
[24]	PARK MH, SONG EY, AHN C, et al. Two subtypes of hepatitis B virus-associated glomerulonephritis are associated with different HLA-DR2 alleles in Koreans[J]. Tissue Antigens, 2003, 62(6): 505-511. DOI: 10.1046/j.1399-0039.2003.00141.x.
[25]	HUI D, YAN X, WEI J, et al. Significance of mutations in hepatitis B virus X gene for the pathogenesis of HB-associated glomerulonephritis[J]. Acta Virol, 2014, 58(3): 278-281. DOI: 10.4149/av_2014_03_278.
[26]	CHENG WR, SUN LJ, DONG HR, et al. Clinical and pathological characteristics of hepatitis B virus -associated glomerulonephritis in adults[J]. Int J Virol, 2021, 28(3): 231-235. DOl: 1073760/maj. sis 1673-4092.2021.03.013. 程文荣, 孙丽君, 董鸿瑞, 等. 成人乙型肝炎病毒相关性肾小球肾炎的临床及病理特点分析[J]. 国际病毒学杂志, 2021, 28(3): 231-235. DOl: 1073760/maj. sis 1673-4092.2021.03.013.
[27]	FRESQUET M, JOWITT TA, GUMMADOVA J, et al. Identification of a major epitope recognized by PLA2R autoantibodies in primary membranous nephropathy[J]. J Am Soc Nephrol, 2015, 26(2): 302-313. DOI: 10.1681/ASN.2014050502.
[28]	XIE Q, LI Y, XUE J, et al. Renal phospholipase A2 receptor in hepatitis B virus-associated membranous nephropathy[J]. Am J Nephrol, 2015, 41(4-5): 345-353. DOI: 10.1159/000431331.
[29]	DONG H, XU Y, XU T, et al. The role of HBx gene mutations in PLA 2R positive hepatitis-B-associated membranous nephropathy[J]. Biomed Environ Sci, 2020, 33(4): 269-272. DOI: 10.3967/bes2020.036.
[30]	TU TQ, ZHENG XM, YANG Y, et al. Role of serum anti-phospholipase A2 receptor antibody level in diagnosis and prognosis assessment of hepatitis B virus-related membranous nephropathy[J]. J Chin Pract Diagn Ther, 2021, 35(1): 7-10. DOI: 10.13507/j.issn.1674-3474.2021.01.002. 涂天琪, 郑旭敏, 杨悦, 等. 血清抗磷脂酶A2受体抗体水平在乙型肝炎病毒相关膜性肾病诊断及预后评估中的价值[J]. 中华实用诊断与治疗杂志, 2021, 35(1): 7-10. DOI: 10.13507/j.issn.1674-3474.2021.01.002.
[31]	RADHAKRISHNAN J, CATTRAN DC. The KDIGO practice guideline on glomerulonephritis: reading between the (guide)lines-application to the individual patient[J]. Kidney Int, 2012, 82(8): 840-856. DOI: 10.1038/ki.2012.280.
[32]	SHAH HH, PATEL C, JHAVERI KD. Complete remission of hepatitis B virus-associated nephrotic syndrome from IgA nephropathy following peginterferon therapy[J]. Ren Fail, 2013, 35(2): 295-298. DOI: 10.3109/0886022X.2012.745785.
[33]	LAI MW, CHANG MH. Updates in the management of hepatitis B in children[J]. Expert Rev Gastroenterol Hepatol, 2019, 13(11): 1065-1076. DOI: 10.1080/17474124.2019.1686975.
[34]	FU B, JI Y, HU S, et al. Efficacy and safety of anti-viral therapy for Hepatitis B virus-associated glomerulonephritis: A meta-analysis[J]. PLoS One, 2020, 15(1): e0227532. DOI: 10.1371/journal.pone.0227532.
[35]	UDOMPAP P, KIM D, AHMED A, et al. Longitudinal trends in renal function in chronic hepatitis B patients receiving oral antiviral treatment[J]. Aliment Pharmacol Ther, 2018, 48(11-12): 1282-1289. DOI: 10.1111/apt.15020.
[36]	Chinese Society of Infectious Diseases, Chinese Medical Association, Chinese Society of Hepatology, Chinese Medical Association. Guidelines for the prevention and treatment of chronic hepatitis B (version 2019)[J]. J Clin Hepatol, 2019, 35(12): 2648-2669. DOI: 10.3969/j.issn.1001-5256.2019.12.007. 中华医学会感染病学分会, 中华医学会肝病学分会. 慢性乙型肝炎防治指南(2019年版)[J]. 临床肝胆病杂志, 2019, 35(12): 2648-2669. DOI: 10.3969/j.issn.1001-5256.2019.12.007.
[37]	NOTSUMATA K, NOMURA Y, TANAKA A, et al. Early changes in tubular dysfunction markers and phosphorus metabolism regulators as a result of switching from entecavir to tenofovir alafenamide fumarate nucleoside analog therapy for chronic hepatitis B patients[J]. Hepatol Res, 2020, 50(3): 402-404. DOI: 10.1111/hepr.13451.
[38]	OGAWA E, NOMURA H, NAKAMUTA M, et al. Tenofovir alafenamide after switching from entecavir or nucleos(t)ide combination therapy for patients with chronic hepatitis B[J]. Liver Int, 2020, 40(7): 1578-1589. DOI: 10.1111/liv.14482.
[39]	ZHENG XY, WEI RB, TANG L, et al. Meta-analysis of combined therapy for adult hepatitis B virus-associated glomerulonephritis[J]. World J Gastroenterol, 2012, 18(8): 821-832. DOI: 10.3748/wjg.v18.i8.821.
[40]	WANG L, YE Z, LIANG H, et al. The combination of tacrolimus and entecavir improves the remission of HBV-associated glomerulonephritis without enhancing viral replication[J]. Am J Transl Res, 2016, 8(3): 1593-1600.
[41]	XIE XF, XIE BY, ZHANG WH, et al. The efficacy and safety of tacrolimus and entecavir combination therapy in the treatment of hepatitis B virus-associated glomerulonephritis: a multi-center, placebo controlled, and single-blind randomized trial[J]. Ann Palliat Med, 2022, 11(5): 1762-1773. DOI: 10.21037/apm-22-328.

Relative Articles

[1]	Yuanqin DU, Meng WANG, Guochu HUANG, Chun YAO, Ruixi ZHONG, Liangjiang HUANG, Jian XU, Jingjing HUANG, Qinwen TAN, Dewen MAO. Therapeutic effect of retention enema with compound rhubarb decoction on a rat model of minimal hepatic encephalopathy based on bile acid metabolomics[J]. Journal of Clinical Hepatology, 2023, 39(10): 2348-2357. doi: 10.3969/j.issn.1001-5256.2023.10.012
[2]	Yebei LIANG, Chunguang YANG, Huadong ZENG, Ruwei TAO, Qiuming HU, Xiaoying TANG, Huaxiang SHI, Wei WU, Xuhong HOU, Weiping JIA. Establishment of screening models for nonalcoholic fatty liver disease in the adult Blang population[J]. Journal of Clinical Hepatology, 2021, 37(12): 2861-2868. doi: 10.3969/j.issn.1001-5256.2021.12.025
[3]	Ruan JingSheng, Chen Chuang, Li KeZhi, Huang Shan, He JianBo, Ceng AiPing, Lian Fang, Wu GuoBin. Expression and significance of semaphorin 3A and its receptor NRP-1 in a rat model of chronic hepatic encephalopathy[J]. Journal of Clinical Hepatology, 2020, 36(6): 1334-1341. doi: 10.3969/j.issn.1001-5256.2020.06.029
[4]	Lin DongYi, Peng Bo, Zheng JingHui, Wang ZongYu, Li HanZhong, He JianBo, Li KeZhi, Wu GuoBin, Chen Chuang. Value of a logistic regression model based on the clinical features of liver cancer in judging the traditional Chinese medicine syndrome types of primary liver cancer[J]. Journal of Clinical Hepatology, 2020, 36(6): 1293-1298. doi: 10.3969/j.issn.1001-5256.2020.06.021
[5]	Gong Man, Zhou Chao, Zhang Ning, Sun KeWei, Zhang ZhenGang, Li HanMin, Li XiuHui, Yang HongZhi, Li Qin, Wang Lin, Zhou XiaoZhou, Mao DeWen, Guo JianChun, Zhuo YunHui, Wang XianBo, Deng Xin, Wang JieFei, Cao WuKui, Zhang ShuQin, Zhang MingXiang, Li Yun. Clinical effect of integrated traditional Chinese and Western medicine therapy in patients with hepatitis B virus-related acute-on-chronic liver failure complicated by hepatic encephalopathy[J]. Journal of Clinical Hepatology, 2018, 34(4): 795-800. doi: 10.3969/j.issn.1001-5256.2018.04.020
[6]	Wang FengJiao, Liu MingJiang, Wu RuiHong, Niu JunQi. A multivariate logistic regression analysis of short-term prognosis of patients with hepatic encephalopathy[J]. Journal of Clinical Hepatology, 2017, 33(4): 711-714. doi: 10.3969/j.issn.1001-5256.2017.04.022
[7]	Hu LiHua, Chen Peng, Wang XiaoLi, Zhang JiYe, Su LianMing, Zhang PeiYi. Relationship between zonula occludens-1 and blood-brain barrier permeability in rats with hepatic encephalopathy[J]. Journal of Clinical Hepatology, 2015, 31(4): 582-584. doi: 10.3969/j.issn.1001-5256.2015.04.025
[8]	Gu LiLi, Wang XianBo. Research progress in noninvasive regression models for liver fibrosis in patients with chronic hepatitis B[J]. Journal of Clinical Hepatology, 2014, 30(7): 691-694. doi: 10.3969/j.issn.1001-5256.2014.07.032
[9]	Wang GuangYi, Shi XiaoJu, Jiang Chao, Sun XiaoDong, Qiu Wei, Lu: GuoYue. One case of liver transplantation for liver failure due to adult- onset Still's disease[J]. Journal of Clinical Hepatology, 2014, 30(1): 67-68. doi: 10.3969/j.issn.1001-5256.2014.01.018
[10]	Gao Rui, Liu ZhongJing, Chen Fei, Gao Lei, Jiang ChuanWu. Multivariate regression analysis of risk factors for HBV-related primary liver cancer[J]. Journal of Clinical Hepatology, 2014, 30(4): 370-372. doi: 10.3969/j.issn.1001-5256.2014.04.021
[11]	Zhang ZhanQing, Lu Wei, Wang YanBing, Jia XiaoFang, Zhang LiJun, Ding RongRong, Zhou XinLan, Feng YanLing. Diagnosis of hepatic fibrosis in hepatitis B patients by logistic regression modeling based on plasma amino acid ratio and age[J]. Journal of Clinical Hepatology, 2013, 29(5): 330-335.
[12]	Zhang WenHua, Jia WenLing, Zhou ZiYing, Tang HaiTao, Wang FengMei. Investigation on the method and safety of the non-heparinized plasma exchange therapy in treating patients with hepatic failure[J]. Journal of Clinical Hepatology, 2012, 28(1): 50-52.
[13]	Zhou XinMin, Dong XuYang. Therapeutic strategies of liver failure for clinical cases[J]. Journal of Clinical Hepatology, 2012, 28(2): 93-98.
[14]	Zhang AiMin, Xin ShaoJie. Virus infection and liver failure[J]. Journal of Clinical Hepatology, 2012, 28(10): 729-731.
[15]	Xu DaHai, Zhang Nan, Gao JinYing, Wu Yang. The therapeutic development of hepatic encephalopathy[J]. Journal of Clinical Hepatology, 2011, 27(2): 218-221.
[16]	Jiang Hao, Xie Qing. Advances in the diagnosis and treatment of hepatic encephalopathy[J]. Journal of Clinical Hepatology, 2011, 27(10): 1027-1031.
[17]	Wang YuMing, Yan ZeHui. The new concepts on hepatic encephalopathy[J]. Journal of Clinical Hepatology, 2010, 26(6): 568-574.
[18]	Li ShuangXing, Shi LiJun, Wang XiuJie. Effects of bone marrow mesenchymal stem cells transplantation into rats with acute liver failure[J]. Journal of Clinical Hepatology, 2010, 26(6): 624-626.
[19]	Liang Jing, Kan ZhiChao, Zhang JianDong. The clinical characteristics and treatment of liver failure patients with spontaneous bacterial peritonitis[J]. Journal of Clinical Hepatology, 2010, 26(6): 621-623.

Supplements(0)

Cited By

Cited by

Periodical cited type(25)

1.	陈炜. 终末期肝病模型联合血清钠评分对肝衰竭患者短期预后的预测价值. 川北医学院学报. 2024(02): 247-251 .
2.	王学英. MELD-Na评分联合NLR预测肝硬化食管胃静脉曲张破裂出血后再出血的临床价值. 罕少疾病杂志. 2024(05): 70-72 .
3.	林小洪，吴文楠，荀振. 血小板-白蛋白-胆红素评分与肝硬化患者肝功能Child-Turcotte-Pugh分级的相关性分析. 福建医科大学学报. 2024(01): 37-43 .
4.	孙玉，秦维，王丹，郑艳丽，霍玉玲. 前白蛋白及纤维蛋白原水平与代偿期肝硬化食管静脉曲张发生的关系. 中国肝脏病杂志(电子版). 2024(02): 7-12 .
5.	石红. 延续性护理服务方案对肝硬化食管胃静脉曲张内镜下精准断流术后的临床影响研究. 基层医学论坛. 2024(20): 114-116+142 .
6.	李欣忆，李娇娇，孙蔚. 肝硬化食管胃底静脉曲张破裂出血患者经颈静脉肝内门体分流术后发生显性肝性脑病的列线图预测模型建立及评价. 临床肝胆病杂志. 2024(08): 1605-1611 . 本站查看
7.	杨丹，周健. 多种无创预测模型在肝硬化门静脉高压中的研究进展. 中国临床研究. 2024(11): 1778-1783 .
8.	陈刚，谷光丽，何映雪，唐尧. 血清表皮生长因子对肝硬化食管胃静脉曲张患者再出血的诊断价值分析. 转化医学杂志. 2024(10): 1698-1702 .
9.	喻雪珂，黎孟玲，彭思远，申月明，梁纶熙，曾亚. 食管胃底静脉曲张破裂出血对肝硬化患者1年死亡结局的影响及相关因素研究. 中国全科医学. 2023(14): 1745-1752 .
10.	郝艳萍，韩靓，仇晶辉，滕圣智，王建华. 乙肝肝硬化食管胃静脉曲张急性出血患者内镜下治疗后发生菌血症的危险因素分析. 中国消毒学杂志. 2023(03): 182-184 .
11.	顾达，童聪，赵祥安，向晓星. PC/SD、FIB-4指数、CTP评分、MELD评分、MELD-Na评分在预测肝硬化食管静脉曲张出血套扎术后1年内再出血的价值评估. 胃肠病学和肝病学杂志. 2023(03): 289-294 .
12.	朱会明，张华，张金荣，吴雪华，吴柳，刘义安. 肝硬化血瘀证患者食管胃底静脉曲张相关性研究. 中国中医急症. 2023(04): 665-668 .
13.	周苏云，周影，程新月. 肝硬化患者发生肝性脑病的影响因素分析及对预检分诊意义的探讨. 中西医结合护理(中英文). 2023(03): 130-132 .
14.	葛琴. 血府逐瘀汤联合双歧杆菌三联活菌治疗酒精性肝硬化的疗效研究. 中医临床研究. 2023(20): 142-145 .
15.	邱荣金，卢劲瑜，苏雪梅，郑凤祥，廖丽芳. 预防使用抗生素对食管胃静脉曲张内镜下治疗的影响评估. 中国现代药物应用. 2023(19): 99-101 .
16.	邢恩涛，赵孟杰，金鹏飞，武振东，刘志春. 肝硬化门静脉高压TIPS术后HVPG下降相关因素. 青岛大学学报(医学版). 2023(05): 759-762 .
17.	刘媛，徐建光，何雪云，万秀萍，林小花，王莉娟，郑临海. 血钙浓度联合MELD评分对肝硬化严重程度的预测价值. 浙江中西医结合杂志. 2022(02): 129-130+149 .
18.	张春燕，田正方，朱经科，晁燕茹. 肝硬化患者食管静脉曲张套扎术后再出血影响因素分析及干预对策. 黑龙江医药科学. 2022(02): 96-99 .
19.	俞斌，屠军，沈玉玲. AIMS65评分预测肝硬化食管胃底静脉曲张破裂出血患者死亡的价值. 胃肠病学和肝病学杂志. 2022(07): 737-742 .
20.	刘益，周自忠，刘刚，徐海荣. 食管胃底静脉曲张破裂出血患者急诊TIPS术后肝性脑病发生特征及危险因素分析. 肝脏. 2022(06): 658-661 .
21.	廖翔. 肝硬化患者SAAG与食管胃底静脉曲张破裂出血的关系研究. 现代诊断与治疗. 2022(11): 1646-1648+1692 .
22.	张春燕，田正方，朱经科，晁燕茹. 肝硬化患者食管静脉曲张套扎术后再出血影响因素分析. 黑龙江医药科学. 2022(05): 171-173 .
23.	曾伍姣，张知洪，陈令民，李亦明. 血管紧张素Ⅱ水平在肝硬化患者诊断中的应用及与MELD评分关系研究. 肝胆外科杂志. 2021(01): 60-63 .
24.	祝强，杨继敏，刘中亮. 八种评分系统对肝硬化失代偿期患者短期预后的预测价值. 中国医药科学. 2021(19): 18-22 .
25.	赵媛，赵明，范玉梅，邵建营. 失代偿期乙型肝炎肝硬化患者不同病毒学应答状态对生存率及肝癌患病率的影响. 中国实用医刊. 2020(23): 50-52 .

Other cited types(9)

Proportional views

Proportional views

通讯作者: 陈斌, bchen63@163.com

1.
沈阳化工大学材料科学与工程学院沈阳 110142

Figures(1)

Get Citation

PDF

XML

Article Metrics

Article views (846) PDF downloads(191)

Research advances in hepatitis B virus-associated glomerulonephritis

DOI: 10.3969/j.issn.1001-5256.2023.03.027